Sotera Health (SHC) has been drawing attention after recent share price moves, with the stock closing at US$18.29. Investors are weighing this latest level against the company’s underlying business and valuation profile.
Recent trading has cooled some of the momentum in Sotera Health, with the share price down 6.25% over the past month but still showing a 5.24% 90 day share price return and a 17.7% total shareholder return over the past year. This hints that sentiment has eased in the short term, while longer term holders have still been rewarded.
Scan Sotera Health alongside a curated group of resilient companies with strong balance sheets using the list of solid balance sheet and fundamentals (23 results) for ideas that match this kind of profile.
Sotera Health now trades at US$18.29 while analyst targets cluster closer to US$22.72, and one intrinsic estimate implies an even steeper discount. Which of these anchors best reflects fair value?
On the most followed fair value view, Sotera Health screens at $22.72 per share versus the recent $18.29 close, putting more weight on long term cash generation than on short term price swings.
The analysts have a consensus price target of $22.72 for Sotera Health based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $321.4 million, and it would be trading on a PE ratio of 26.4x, assuming you use a discount rate of 8.9%.
See why 1 investors see Sotera Health as 20% undervalued.
Result: Fair Value of $22.72 (UNDERVALUED)
Still, Sotera Health faces real pressure if ethylene oxide regulations tighten further or if high compliance and capex needs reduce future cash generation and flexibility.
Find out about the key risks to this Sotera Health narrative.
Mixed signals on Sotera Health so far. If you want to move beyond headlines and sentiment, start with the underlying numbers and weigh the 4 key rewards and 2 important warning signs.
Do not stop with Sotera Health alone. Broaden your watchlist using focused lists of companies filtered for quality, value, and resilience that many investors overlook.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com